DxS to Provide K-RAS Companion Diagnostic for Erbitux

DxS has entered into a collaboration agreement with Bristol-Meyers Squibb and ImClone Systems to further develop a K-RAS companion diagnostic for Erbitux in the U.S. and Canada, according to a company statement. The DxS TheraScreen: K-RAS mutation kit would be used with Erbitux in metastatic colorectal cancer (mCRC) to determine which patients have wild-type K-RAS status. About 60 percent of patients with mCRC have the wild-type K-RAS gene, the statement says. The test has yet to be approved by the FDA.